Economic Rules Hub
  • World
  • Politics
  • Business
  • Investing
Home Investing Cleo Commences U.S. Clinical Trials
Investing

Cleo Commences U.S. Clinical Trials

by admin September 6, 2024
September 6, 2024

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to confirm the commencement of U.S. clinical trials for its ovarian cancer diagnostic blood test.

Highlights

U.S. clinical trials commenced with first patients enrolled over 8 recruitment centresTrial will validate the use of CLEO’s ovarian cancer blood test for the U.S. marketPathway set toward FDA submission in CY2025.

Commencement of U.S. Clinical Trials

CLEO’s pivotal FDA-enabling clinical trial has commenced in the United States, with first patients recruited into the study. The trial is designed to benchmark CLEO’s technology, with recruitment targeting a minimum of 500 patients with diversity representative of the U.S. population. The data collected will underpin a submission to the Food and Drug Administration (FDA) seeking approval for clinical use of CLEO’s ovarian cancer detection blood test in the world’s largest diagnostic market.

Eight participating medical institutions, located across 6 U.S. states, are currently recruiting patients. Eligible patients at these sites will be identified by their primary physician and given the opportunity to participate during their consultation. Additional sites may also be included as the trial progresses.

Commenting on the commencement of U.S. clinical trials, CLEO Chief Executive, Richard Allman, said:

“Commencement of our U.S. trials confirm a significant milestone for CLEO and sets a clear pathway now for our planned entry into the U.S. market.

We have already demonstrated that CLEO’s ovarian cancer blood test is highly accurate, can detect early-stage cancer, and importantly is significantly better than clinical tools used today. This gives us confidence in moving through the trial activities to enable our FDA submission.

It is important to note that no diagnostic test exists today for ovarian cancer. Diagnosis can only be made after surgery. The opportunity in front of us is immense and CLEO is well positioned and funded to achieve access into our initial pre-surgery test market.”

Click here for the full ASX Release

This post appeared first on investingnews.com

0
FacebookTwitterPinterestEmail
previous post
Arcadium Halts Mount Cattlin Expansion, Plans Transition to Care and Maintenance
next post
Senate GOP campaign chair ‘concerned’ over fundraising disparity but predicts who will win majority

Related Posts

Trailbreaker Resources Announces Exchange Approval Of COHO Property Option

June 7, 2025

How AI is Poised to Rewire the Foundations of Medicine

June 7, 2025

Web Summit 2025: AI Innovation, Investment Shifts and Global Tech...

June 7, 2025

Ford Government Pushes Bill 5 Through Legislature, Sparking First Nations...

June 7, 2025

Hempalta Provides Strategic Update Regarding Equipment Sale and FCC Agreement

June 7, 2025

Editor’s Picks: Marathon Project Gets Nod, Rio Tinto Opens Western...

June 7, 2025

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent

    • Planned Russia-Ukraine prisoner swap descends into blame game and uncertainty

      June 8, 2025
    • Bruce Springsteen’s European tour comes with a warning about the battle for America’s soul

      June 8, 2025
    • Israel says it has killed leader of Palestinian militant group that took part in October 7 attack

      June 8, 2025
    • Colombian presidential hopeful Miguel Uribe shot in Bogota

      June 8, 2025
    • Desperate to get its illegally detained civilians out of Russia, Kyiv offers Ukrainian collaborators in exchange

      June 8, 2025

    Categories

    • Business (1,395)
    • Investing (3,407)
    • Politics (4,562)
    • World (4,471)
    • Email Whitelisting
    • Terms and Conditions
    • Privacy Policy
    • Contacts
    • About us

    Disclaimer: EconomicRulesHub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 EconomicRulesHub.com | All Rights Reserved

    Economic Rules Hub
    • World
    • Politics
    • Business
    • Investing